drugset / Trial / NCT04351191
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
Phase 4
Terminated
137 enrolled
Government of Punjab, Specialized Healthcare and Medical Education Department
Mayo Hospital Lahore · collabPakistan Kidney and Liver Institute · collabServices Hospital, Lahore · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.
Timeline
- Start
- 2020-04-15
- Primary completion
- 2020-08-23
- Completion
- 2020-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Chloroquine | Small molecule | 500 mg | — |
| Comparator | Hydroxychloroquine | Small molecule | 200 mg | — |
| Comparator | Hydroxychloroquine | Small molecule | 400 mg | — |